Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns
| Autor: | José Luis García Fierro, Ester Vázquez, Maurizio Prato, Alessia Scarsi, Marcella Pinto, María Isabel Lucío, Giulio Fracasso, María Antonia Herrero, Roberta Opri, Moreno Meneghetti |
|---|---|
| Přispěvatelé: | LUCÍO BENITO, MARIA ISABEL, Opri, Roberta, Pinto, Marcella, Scarsi, Alessia, Fierro, Jose L. G., Meneghetti, Moreno, Fracasso, Giulio, Prato, Maurizio, Vázquez, Ester, HERRERO CHAMORRO, MARIA ANTONIA |
| Rok vydání: | 2020 |
| Předmět: |
Materials science
medicine.drug_class Biomedical Engineering 02 engineering and technology Pharmacology 010402 general chemistry Monoclonal antibody 01 natural sciences carbon nanohorns prostate cancer antibody conjugates Carbon Nanohorns Prostate cancer carbon nanohorn Antigen medicine General Materials Science Nanomaterials Cancer Prostate Cancer (PCa) General Chemistry General Medicine Prostate-specific membrane antigen (PSMA) Prodrug 021001 nanoscience & nanotechnology medicine.disease 0104 chemical sciences Antobody Drug delivery Cancer cell Cancer research Nanohorns antibody-drug nanosystem 0210 nano-technology Conjugate |
| Zdroj: | RUIdeRA. Repositorio Institucional de la UCLM instname |
| ISSN: | 2050-7518 |
| Popis: | The ability of carbon nanohorns (CNHs) to cross biological barriers makes them potential carriers for delivery purposes. In this work, we report the design of a new selective antibody-drug nanosystem based on CNHs for the treatment of prostate cancer (PCa). In particular, cisplatin in a prodrug form and the monoclonal antibody (Ab) D2B, selective for PSMA+ cancer cells, have been attached to CNHs due to the current application of this antigen in PCa therapy. The hybrids Ab-CNHs, cisplatin-CNHs and functionalised- CNHs have been also synthesized to be used as control systems. The efficacy and specificity of the D2B-cisplatin-CNHs conjugate to selectively target and kill PSMA+ prostate cancer cells have been demonstrated in comparison with the other derivatives. The developed strategy to functionalise CNHs is fascinating because it can allow a fine tuning of both drug and Ab molecules attached to the nanostructure in order to modulate the activity of the nanosystem. Finally, the herein described methodology can be used for the incorporation of almost any drugs or Abs in the platforms in order to create new targeted drugs for the treatment of different diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|